SLRN241115P5000
- 0.20
- 0.000.00%
Acelyrin Newsroom
ACELYRIN Is Maintained at Overweight by Wells Fargo
Acelyrin Analyst Ratings
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating, Raises Target Price to $15
Express News | ACELYRIN Inc : Wells Fargo Raises Target Price to $15 From $13
Promising Outlook for ACELYRIN's Izokibep in Uveitis Treatment Drives Buy Recommendation
Jasper Gains 11% on Data for Briquilimab in Urticaria
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 11%
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
ACELYRIN, INC. (SLRN) Receives a Buy From Piper Sandler
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
Acelyrin Spikes as Late-stage Data for Lead Asset Selected for Medical Event
Sector Update: Health Care Stocks Rise Premarket Thursday
Acelyrin Says Late-Stage Izokibep Trial Shows Statistically Significant Results
Express News | ACELYRIN, Inc. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at Eadv 2024
ACELYRIN, INC. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
ACELYRIN, INC. to Participate in Upcoming Investor Conferences